TY - JOUR
T1 - In cancer, all roads lead to NADPH
AU - Rather, Gulam Mohmad
AU - Pramono, Alvinsyah Adhityo
AU - Szekely, Zoltan
AU - Bertino, Joseph R.
AU - Tedeschi, Philip Michael
N1 - Funding Information:
This work was supported by Rutgers Cancer Institute of New Jersey (grant number 812407 ).
Publisher Copyright:
© 2021
PY - 2021/10
Y1 - 2021/10
N2 - Cancer cells require increased levels of NADPH for increased nucleotide synthesis and for protection from ROS. Recent studies show that increased NADPH is generated in several ways. Activated AKT phosphorylates NAD kinase (NADK), increasing its activity. NADP formed, is rapidly converted to NADPH by glucose 6-phosphate dehydrogenase and malic enzymes, overexpressed in tumor cells with mutant p53. Calmodulin, overexpressed in some cancers, also increases NADK activity. Also, in IDH1/2 mutant cancer, NADPH serves as the cofactor to generate D-2 hydroxyglutarate, an oncometabolite. The requirement of cancer cells for elevated levels of NADPH provides an opportunity to target its synthesis for cancer treatment.
AB - Cancer cells require increased levels of NADPH for increased nucleotide synthesis and for protection from ROS. Recent studies show that increased NADPH is generated in several ways. Activated AKT phosphorylates NAD kinase (NADK), increasing its activity. NADP formed, is rapidly converted to NADPH by glucose 6-phosphate dehydrogenase and malic enzymes, overexpressed in tumor cells with mutant p53. Calmodulin, overexpressed in some cancers, also increases NADK activity. Also, in IDH1/2 mutant cancer, NADPH serves as the cofactor to generate D-2 hydroxyglutarate, an oncometabolite. The requirement of cancer cells for elevated levels of NADPH provides an opportunity to target its synthesis for cancer treatment.
KW - Calmodulin
KW - NAD
KW - NAD kinase
KW - NADPH
KW - ROS
UR - http://www.scopus.com/inward/record.url?scp=85105836064&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105836064&partnerID=8YFLogxK
U2 - 10.1016/j.pharmthera.2021.107864
DO - 10.1016/j.pharmthera.2021.107864
M3 - Review article
C2 - 33894275
AN - SCOPUS:85105836064
SN - 0163-7258
VL - 226
JO - Pharmacology and Therapeutics, Part A: Chemotherapy, Toxicology and
JF - Pharmacology and Therapeutics, Part A: Chemotherapy, Toxicology and
M1 - 107864
ER -